CADPT09A12201: A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis

The purpose of this proof-of-concept platform study is to determine whether
selected systemic investigational products have an adequate clinical profile to
support further clinical development in mild to moderate IPF. This platform
design allows several investigational drugs